论文部分内容阅读
目的探讨瑞舒伐他汀对冠心病患者心功能、血脂水平及血液流变学指标的影响。方法选取2012年3月—2015年7月赣州市中医院收治的确诊为冠心病患者81例,按照随机数字表法分为对照组40例与治疗组41例。对照组给予常规治疗,治疗组在对照组基础上给予瑞舒伐他汀治疗。比较两组患者治疗前及治疗后血脂指标〔总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)〕、心功能指标〔左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左室射血分数(LVEF)〕、血液流变学指标〔纤维蛋白原(Fib)、血浆黏度、血黏度(低切、高切)〕及不良反应发生情况。结果治疗前两组患者TC、TG、LDL-C水平比较,差异无统计学意义(P>0.05);治疗后治疗组患者TC、TG、LDL-C水平低于对照组,差异有统计学意义(P<0.05);治疗后治疗组TC、TG、LDL-C水平低于治疗前,差异有统计学意义(P<0.05)。治疗前两组患者LVESV、LVEDV、LVEF比较,差异无统计学意义(P>0.05);治疗后治疗组患者LVESV、LVEDV低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者Fib、血浆黏度、血黏度水平比较,差异无统计学意义(P>0.05);治疗后治疗组患者Fib、血浆黏度、血黏度水平低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀治疗冠心病可更好地改善患者心功能、血脂水平及血液流变学指标。
Objective To investigate the effect of rosuvastatin on cardiac function, blood lipid and hemorheology in patients with coronary heart disease. Methods From March 2012 to July 2015, 81 patients with coronary heart disease admitted to Ganzhou Hospital of Traditional Chinese Medicine were divided into control group (n = 40) and treatment group (n = 41) according to random number table. The control group was given routine treatment, the treatment group was given rosuvastatin on the basis of the control group. The levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) before and after treatment were compared between the two groups. Cardiac function indexes such as left ventricular end-diastolic volume Left ventricular end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF)), hemorheological parameters (Fib, plasma viscosity, blood viscosity (low and high) and incidence of adverse reactions . Results There was no significant difference in the levels of TC, TG and LDL-C between the two groups before treatment (P> 0.05). The levels of TC, TG and LDL-C in the treatment group after treatment were lower than those in the control group (P <0.05). After treatment, the levels of TC, TG and LDL-C in the treatment group were lower than those before treatment, the difference was statistically significant (P <0.05). LVESV, LVEDV and LVEF in the two groups before treatment were not significantly different (P> 0.05). After treatment, the LVESV and LVEDV in the treatment group were lower than those in the control group, and the LVEF was higher in the treatment group than in the control group (P < 0.05). There was no significant difference in Fib, plasma viscosity and blood viscosity between the two groups before treatment (P> 0.05). After treatment, Fib, plasma viscosity and blood viscosity in the treatment group were lower than those in the control group P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Rosuvastatin treatment of coronary heart disease can better improve the patient’s cardiac function, blood lipid levels and hemorheological parameters.